- Nachrichtendetail
-
01.11.2023 07:20:30 - Spexis Announces Changes to the Executive Committee
===
Spexis AG / Key word(s): Personnel/Personnel
Spexis Announces Changes to the Executive Committee
01-Nov-2023 / 07:20 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement pursuant to Art. 53 LR
Spexis Announces Changes to the Executive Committee
Allschwil, Switzerland, November 1, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases
and oncology, today announced that Hernan Levett, currently Chief Financial Officer, has decided to pursue a new career
opportunity outside the company. He will continue to support the company as a strategic advisor on financial
transactions and will depart the company effective December 1, 2023. Martin Jakobovic, currently Head of Finance, will
succeed Hernan Levett as interim Chief Financial Officer joining the Executive Committee on December 1, 2023.
Additionally, Muriel Fleming, currently Head of Human Resources, will assume additional responsibilities related to
administration and facilities, as well as joining the Executive Committee of Spexis also on December 1, 2023.
"On behalf of the entire Spexis team and the board of directors, I would like to thank Hernan for his dedication and
contributions to the company since its inception in December 2021," said Jeff Wager, M.D., Chairman & CEO of Spexis.
"Hernan has been a very valuable member of the management team and we wish him all the best in his future endeavors. I
look forward to collaborating with Martin, whose leadership skills and knowledge of the company will prove invaluable
in achieving our current goals. I would also like to congratulate Muriel on her appointment to the Executive Committee
where she will continue to provide important insight on Spexis' corporate strategy and development efforts."
"After being intimately involved in the formation of Spexis and as Chief Financial Officer since, it is time for me to
take on a new challenge," remarked Hernan Levett. "I would like to thank Jeff, the board of directors, our
shareholders, and the entire Spexis team for their trust, support, and commitment. It has been a pleasure to serve the
company and I wish the team all the best as they move into an exciting chapter in the company's future."
Biographical summaries of Martin and Muriel can be found on our website www.spexisbio.com
About Spexis
Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle
therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.
For further information please contact:
For Investors:
Stephen Jasper
Managing Director
Gilmartin Group
stephen@gilmartinir.com
For Media:
Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch
===
Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis' results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
-----------------------------------------------------------------------------------------------------------------------
End of Inside Information
-----------------------------------------------------------------------------------------------------------------------
===
Hegenheimermattweg 125
4123 Allschwil
Switzerland
End of Announcement EQS News Service
===
1762049 01-Nov-2023 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1762049&application_name=news
END) Dow Jones Newswires
November 01, 2023 02:20 ET (06:20 GMT)
Spexis AG / Key word(s): Personnel/Personnel
Spexis Announces Changes to the Executive Committee
01-Nov-2023 / 07:20 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement pursuant to Art. 53 LR
Spexis Announces Changes to the Executive Committee
Allschwil, Switzerland, November 1, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases
and oncology, today announced that Hernan Levett, currently Chief Financial Officer, has decided to pursue a new career
opportunity outside the company. He will continue to support the company as a strategic advisor on financial
transactions and will depart the company effective December 1, 2023. Martin Jakobovic, currently Head of Finance, will
succeed Hernan Levett as interim Chief Financial Officer joining the Executive Committee on December 1, 2023.
Additionally, Muriel Fleming, currently Head of Human Resources, will assume additional responsibilities related to
administration and facilities, as well as joining the Executive Committee of Spexis also on December 1, 2023.
"On behalf of the entire Spexis team and the board of directors, I would like to thank Hernan for his dedication and
contributions to the company since its inception in December 2021," said Jeff Wager, M.D., Chairman & CEO of Spexis.
"Hernan has been a very valuable member of the management team and we wish him all the best in his future endeavors. I
look forward to collaborating with Martin, whose leadership skills and knowledge of the company will prove invaluable
in achieving our current goals. I would also like to congratulate Muriel on her appointment to the Executive Committee
where she will continue to provide important insight on Spexis' corporate strategy and development efforts."
"After being intimately involved in the formation of Spexis and as Chief Financial Officer since, it is time for me to
take on a new challenge," remarked Hernan Levett. "I would like to thank Jeff, the board of directors, our
shareholders, and the entire Spexis team for their trust, support, and commitment. It has been a pleasure to serve the
company and I wish the team all the best as they move into an exciting chapter in the company's future."
Biographical summaries of Martin and Muriel can be found on our website www.spexisbio.com
About Spexis
Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle
therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.
For further information please contact:
For Investors:
Stephen Jasper
Managing Director
Gilmartin Group
stephen@gilmartinir.com
For Media:
Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch
===
Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis' results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
-----------------------------------------------------------------------------------------------------------------------
End of Inside Information
-----------------------------------------------------------------------------------------------------------------------
===
Language: English Company: Spexis AG
Hegenheimermattweg 125
4123 Allschwil
Switzerland
Phone: +41 61 567 1600 Fax: +41 61 567 1601 E-mail: info@spexisbio.com Internet: www.spexisbio.com ISIN: CH0106213793 Valor: SPEX Listed: SIX Swiss Exchange EQS News ID: 1762049
End of Announcement EQS News Service
===
1762049 01-Nov-2023 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1762049&application_name=news
END) Dow Jones Newswires
November 01, 2023 02:20 ET (06:20 GMT)
